Home

FAQ

1.Where is Tengion headquartered?
2.What year was Tengion incorporated and in what state?
3.On what exchange is Tengion listed and under what stock symbol?
4.How can I purchase shares?
5.When does the fiscal year end?
6.Who is Tengion’s transfer agent?
7.Who are Tengion’s independent auditors?
8.Who is Tengion’s outside legal counsel?
9.Who should I contact if I have any questions?
1.Where is Tengion headquartered?
 Tengion is headquartered in Winston-Salem, North Carolina.

2.What year was Tengion incorporated and in what state?
 Tengion was incorporated in the State of Delaware on July 10, 2003.

3.On what exchange is Tengion listed and under what stock symbol?
 Tengion is traded on the OTC Markets under the symbol TNGN.

4.How can I purchase shares?
 Shares can be purchased through a stockbroker of your choice. Tengion does not have a direct stock purchase plan.

5.When does the fiscal year end?
 December 31

6.Who is Tengion’s transfer agent?
 Tengion's Transfer Agent and Registrar is American Stock Transfer and Trust Company (www.amstock.com; 800-937-5449)

7.Who are Tengion’s independent auditors?
  Ernst and Young
Two Commerce Square
2001 Market Street, Suite 4000
Philadelphia, PA 19103
(215) 448-5000

8.Who is Tengion’s outside legal counsel?
 Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

9.Who should I contact if I have any questions?
 Brian Davis
Chief Financial Officer and Senior Vice President, Finance
ir@tengion.com

Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.16
Change (%)0.00 (0.00%)
Volume33,063
Data as of 07/25/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
May 15, 2014
Tengion Reports First Quarter 2014 Financial Results
WINSTON-SALEM, N.C., May 15, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the first quarter ended March 31, 2014. "We are actively continuing patient enrollment in our ongoing Phase 1 clinical trials for the Neo-Kidney Augment in both Sweden and in the United States. We are also working with key opinion leaders to determine future development plans for the Neo-Urinary Conduit," commented John L. Miclot, Presi... 
March 26, 2014
Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
WINSTON-SALEM, N.C., March 26, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update. "We made important progress on our two lead clinical programs over the last year. We now have two Phase 1 clinical trials ongoing for the Neo-Kidney Augment, one in Sweden and the other recently initiated in the U.S. to implant up to 12 patients. ...